Additional Proxy Soliciting Materials (definitive) (defa14a)
June 03 2014 - 9:05AM
Edgar (US Regulatory)
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.___)
Filed by the Registrant
T
Filed by a Party other than the Registrant
£
Check the appropriate box:
£
Preliminary Proxy Statement
£
Definitive Proxy Statement
£
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
T
Definitive Additional Materials
£
Soliciting Material Pursuant to 240.14a-12
MMRGLOBAL, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
T
No fee required.
£
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
______________________________________________________________________________________________
(2) Aggregate number of securities to which transaction applies:
______________________________________________________________________________________________
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth
the amount on which the filing fee is calculated and state how it was determined):
______________________________________________________________________________________________
(4) Proposed maximum aggregate value of transaction:
______________________________________________________________________________________________
(5) Total fee paid:
______________________________________________________________________________________________
£
Fee paid previously with preliminary materials.
£
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
______________________________________________________________________________________________
(2) Form, Schedule or Registration Statement No.:
______________________________________________________________________________________________
(3) Filing Party:
______________________________________________________________________________________________
(4) Date Filed:
______________________________________________________________________________________________
FOR IMMEDIATE RELEASE
MMRGlobal Announces No Increase in Authorized Shares Due to
Record Sales & Licensing Revenues
Los Angeles, California (June 2, 2014) -
MMRGlobal, Inc
. (OTCQB: MMRF) (the "Company") today announced that for the first time in two years, the Company
will not be requesting an increase in its authorized shares of common stock going into its Annual Meeting scheduled for July 16, 2014. Based
on recent operating trends, including sales of its
MyMedicalRecords
Personal Health Record (PHR), licensing revenues and projected sales at retail, the Company does not foresee having to request
additional shares to fund its ordinary working capital needs for this year. MMRGlobal reported record revenue for the first quarter of 2014 and
projects that overall this operating trend will continue throughout CY 2014. Furthermore, the Company looks forward to announcing at least two
significant patent licensing settlement agreements involving existing defendants and others in the current quarter. The Company also called
attention to an article in
Healio
that appeared yesterday
entitled "
Lenalidomide, rituximab achieved responses in treatment-naive patients with follicular lymphoma
."
Information contained in the article appears to be significant toward the meeting of
milestones contained in thirteen million dollars of non-exclusive license agreement(s) with a major biopharmaceutical company. The
agreements pertain to allowing big pharma to access and utilize certain of the Company's pre-merger biotech assets and other data to help
expedite FDA and European market approvals of Revlimid® (lenalidomide) in the treatment of follicular lymphoma. Details can be found on
Form 8-K
in the Company's filings with the SEC.
The Company, through its wholly owned subsidiary, MyMedicalRecords, Inc. (collectively, "MMR"), is a leading provider of
Personal Health Records
,
MyEsafeDepositBox
storage solutions and MMRPro document management and imaging
systems for
healthcare professionals
. MMR is a practicing
entity with 11 U.S. health IT patents including U.S. Patent Nos. 8,121,855; 8,117,045; 8,117,646; 8,301,466; 8,321,240; 8,352,287; 8,352,288;
8,498,883; 8,626,532; 8,645,161 and 8,725,537, which collectively include over 275 issued claims, along with additional applications and
continuation applications pending. MMR also has issued patents and pending applications in 11 other countries or regional authorities of
commercial interest including Australia, Canada, Singapore, New Zealand, Mexico, Hong Kong, China, Japan, South Korea, Israel, and
Europe.
Although MMR's primary business is as a provider and licensor of health IT products and services, the Company also has a portfolio of
biotech patents. These pertain to cancer-fighting anti-CD20 monoclonal antibodies under the title, "Antibodies and Methods For Making and
Using Them," issued in the U.S., Mexico, Australia and South Korea, with patents pending in the U.S., Australia, Brazil, Canada, China, Hong
Kong, India, Europe, Japan and Korea, and additional patents pertaining to its B-cell idiotype vaccine worldwide.
About MMRGlobal
MMRGlobal, Inc., through its wholly-owned subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal
Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers,
insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The
MyMedicalRecords
PHR enables individuals and families to access their medical
records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the
Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be
transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic
medical record platform to populate a user's account. MMR's professional offering,
MMRPro
, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based
2/
medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille,
Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its
FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc.
visit
www.mmrglobal.com
. View demos and video tutorials of
MMR's products and services at
www.mmrtheater.com
.
Follow us at
Facebook.com/MMRGlobal
and
Twitter.com/mmrglobal
.
Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property licenses,
intellectual property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs,
intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results
expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need,"
"possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect,"
"maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events
may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance.
Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those
relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business,
industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including
customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and
officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to
intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to
maintain, develop, license, monetize and protect our patent portfolio for both MMR's health IT and biotechnology intellectual property assets in
the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and
maintain strategic relationships; changes in our relationships with our licensees; the risk MMR's products are not adopted or viewed favorably
by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the
current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and
installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions;
competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in
Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors
in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating
third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key
personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional
risks discussed in MMR's filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this
release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in
this release as a result of new information, future events or otherwise.
###
CONTACT:
Michael Selsman
Public Communications Co.
ms@publiccommunications.biz
(310) 922-7033